The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A pyrrolotriazine that is pyrrolo[2,1-f][1,2,4]triazine which is substituted at position 2 by the pyrrolidine nitrogen of (2S)-N-(6-fluoropyridin-3-yl)-2-methylprolinamide, and at position 4 by a (5-cyclopropyl-1H-pyrazol-3-yl)amino group. It is a potent, reversible inhibitor of the insulin-like growth factor 1 receptor/insulin receptor family kinases.
BMS 754807 results in decreased phosphorylation of AKT1 protein BMS 754807 inhibits the reaction [palbociclib results in increased phosphorylation of AKT1 protein]
[BMS 754807 co-treated with palbociclib] results in increased expression of CCND1 protein; [CCND1 mutant form results in increased susceptibility to BMS 754807] which results in decreased phosphorylation of RPS6KB1 protein
[[CDK4 mutant form co-treated with CDK6 mutant form] results in increased susceptibility to BMS 754807] which results in decreased phosphorylation of RPS6KB1 protein; [CDK4 mutant form co-treated with CDK6 mutant form] results in increased susceptibility to BMS 754807
[[CDK4 mutant form co-treated with CDK6 mutant form] results in increased susceptibility to BMS 754807] which results in decreased phosphorylation of RPS6KB1 protein; [CDK4 mutant form co-treated with CDK6 mutant form] results in increased susceptibility to BMS 754807
[BMS 754807 co-treated with palbociclib] results in decreased phosphorylation of IGF1R protein BMS 754807 results in decreased phosphorylation of IGF1R protein
BMS 754807 promotes the reaction [palbociclib results in decreased phosphorylation of RB1 protein] BMS 754807 results in decreased phosphorylation of RB1 protein RB1 mutant form results in decreased susceptibility to BMS 754807
BMS 754807 results in decreased phosphorylation of RPS6KB1 protein [[CDK4 mutant form co-treated with CDK6 mutant form] results in increased susceptibility to BMS 754807] which results in decreased phosphorylation of RPS6KB1 protein; [CCND1 mutant form results in increased susceptibility to BMS 754807] which results in decreased phosphorylation of RPS6KB1 protein; palbociclib promotes the reaction [BMS 754807 results in decreased phosphorylation of RPS6KB1 protein]